Open AccessEfficacy and Safety of a Weight-based Dosing Regimen of Valganciclovir for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients
Author(s) -
A Pappo,
Orit Peled,
Matitiahu Berkovitch,
Efraim Bilavsky,
Eran Rom,
Jacob Amir,
Irit Krause,
Havatzelet Yarden-Bilavsky,
Oded Scheuerman,
Liat AshkenaziHoffnung
Publication year - 2019
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002632
Subject(s) - valganciclovir , medicine , regimen , dosing , adverse effect , asymptomatic , cytomegalovirus , antibiotic prophylaxis , ganciclovir , gastroenterology , surgery , human cytomegalovirus , immunology , herpesviridae , viral disease , antibiotics , human immunodeficiency virus (hiv) , virus , microbiology and biotechnology , biology
Valganciclovir has been widely used for cytomegalovirus (CMV) prophylaxis in solid-organ transplant recipients. However, the optimal dosing protocol and target exposure in children are still unclear. Specific data as to the efficacy and safety of low-dose/low-exposure regimens are lacking and urgently needed.